Zilongjin

Developed for: non-small cell lung carcinoma
Investigated by: Kong Fanming · Ministry of Science and Technology of the People´s Republic of China

today NCT07034326 · Ph 2/3

20252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2/3	NCT07034326	Jan 2025 → Dec 2028 expected	non-small cell lung carcinoma	Kong Fanming	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Zilongjin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07034326 ↗
Route	Oral	“Take Zilongjin tablets orally, 4 tablets each time, 3 times a day.” NCT07034326 ↗